Fluticasone Nasal; EDS-FLU (Xhance)

Introduction

Tradename: Xhance (FDA-approved April 2024)

Indications

• treatment of allergic rhinosinusitis without nasal polyps

Mechanism of action

• intranasal glucocorticoid
• EDS-Flu (Xhance) is a device that works by blowing into a mouthpiece as the spray is actuated
  • this allows for deposition of fluticasone above the middle meatus to the ostiomeatal complex & sinus openings

Notes

• cash pric $800/month

More general terms

• fluticasone (Flonase, Veramyst, Flovent, Arnuity Ellipta)
• nasal agent